Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
NCT03434730 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 7, 2018
- Completion date
- April 18, 2025
- Enrollment
- 46 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, hodgkin lymphoma, leukemia, myelodysplastic syndromes, myelodysplastic-myeloproliferative diseases, myeloproliferative disorder, non hodgkin lymphoma